Product
Irinotecan
Aliases
Campto, Camptosar, CAMPTOSAR®, Camptothecin 11, Camptothecin-11 (19 other aliases)
96 clinical trials
1 abstract
219 indications
Indication
Esophageal squamous cell carcinomaIndication
Ewing SarcomaIndication
Solid TumorsIndication
Rhabdoid TumorIndication
RhabdomyosarcomaIndication
NeuroblastomaIndication
MedulloblastomaIndication
Diffuse Intrinsic Pontine GliomaIndication
Refractory CancerIndication
Refractory NeoplasmIndication
Pediatric CancerIndication
Refractory TumorIndication
Pediatric Brain TumorIndication
Neuroblastoma RecurrentIndication
LymphomaIndication
Pediatric MeningiomaIndication
Brain TumorIndication
RecurrentIndication
PediatricIndication
Central Nervous System NeoplasmsIndication
Childhood Solid TumorIndication
Protocol SpecificIndication
Advanced Solid TumorsIndication
Biliary Tract CancerIndication
Advanced Solid TumorIndication
CancerIndication
Esophageal Squamous Cell CarcinomaIndication
Solid TumorIndication
Colorectal CancerIndication
CholangiocarcinomaIndication
Bladder CancerIndication
Ovarian CancerIndication
Stomach CancerIndication
Palpable Subcutaneous Malignant LesionsIndication
Renal Cell CarcinomaIndication
MelanomaIndication
Primary Peritoneal CancerIndication
Fallopian tube cancerIndication
Metastatic Colorectal CancerIndication
SarcomaIndication
Ewing sarcomaIndication
MetastasisIndication
Esophageal CancerIndication
Pancreatic adenocarcinomaIndication
Small Cell Lung CancerIndication
Advanced Malignant NeoplasmIndication
GlioblastomaIndication
Soft Tissue SarcomaIndication
Endometrial CancerIndication
MesotheliomaIndication
GEP-NETIndication
small cell lung cancerIndication
Colorectal cancerIndication
Neuroendocrine TumorsIndication
AdolescentIndication
Advanced CancerIndication
Metastatic CancerIndication
cancerIndication
Non-Small Cell LungIndication
Ovarian Epithelial CancerIndication
Pancreatic CancerIndication
Refractory Non-Hodgkin LymphomaIndication
Bone NeoplasmIndication
TumorIndication
BreastIndication
Lung NeoplasmIndication
Colorectal neoplasmsIndication
Pancreatic NeoplasmsIndication
Malignant GliomaIndication
MalignancyIndication
Malignant NeoplasmsIndication
Bone metastasesIndication
Bone TumorIndication
bone cancerIndication
Breast NeoplasmsIndication
Acute T Cell Leukemia LymphomaIndication
Rare DiseasesIndication
Connective and Soft TissueIndication
NeoplasmsIndication
bone tissueIndication
connective tissueIndication
cervical cancerIndication
OncologyIndication
Advanced Gastrointestinal CancerIndication
Small Cell Lung CarcinomaIndication
Metastatic Malignant Solid NeoplasmIndication
Lung Small Cell CarcinomaIndication
Malignant Solid NeoplasmIndication
Stage III Lung Cancer AJCC v8Indication
Stage III Pancreatic CancerIndication
Colorectal Cancer stage IV AJCC v8Indication
Stage IV Lung CancerIndication
Pancreatic Acinar Cell AdenocarcinomaIndication
Pancreatic Ductal AdenocarcinomaIndication
Stage IIB Pancreatic CancerIndication
Unresectable Pancreatic CarcinomaIndication
Breast Cancer MetastaticIndication
Digestive System CarcinomaIndication
Gastroesophageal Junction AdenocarcinomaIndication
Stage III Gastric CancerIndication
Stage IV Gastric CancerIndication
Childhood Solid NeoplasmIndication
Recurrent Malignant Solid NeoplasmIndication
Central Nervous System Embryonal TumorIndication
NOSIndication
GanglioneuroblastomaIndication
C19MC-ModifiedIndication
PineoblastomaIndication
Primary Central Nervous System NeoplasmIndication
Colorectal AdenocarcinomaIndication
Rectal CancerIndication
RAS MutationIndication
MSSIndication
Brain and Central Nervous System TumorsIndication
Colon CancerIndication
ERBB2 Gene AmplificationIndication
Rectal AdenocarcinomaIndication
Recurrent Colorectal CancerIndication
Stage IIIA Colon CancerIndication
Stage IIIA Rectal CancerIndication
Pancreatic Cancer, Stage 0 (AJCC v8)Indication
Pancreatic Cancer, Stage I AJCC v8Indication
Stage IV Pancreatic CancerIndication
Stage IV Colon Cancer AJCC v7Indication
Rectal Cancer, Stage IVA (AJCC v7)Indication
Anaplastic AstrocytomaIndication
Recurrent Anaplastic OligoastrocytomaIndication
OligodendrogliomaIndication
GliosarcomaIndication
Recurrent Malignant GliomaIndication
Recurrent WHO Grade III GliomaIndication
BRAFIndication
KRAS wild type AlleleIndication
NeoplasmIndication
Alveolar RhabdomyosarcomaIndication
Botryoid-type Embryonal RhabdomyosarcomaIndication
Spindle Cell RhabdomyosarcomaIndication
Small Intestinal AdenocarcinomaIndication
Small Intestinal Adenocarcinoma AJCC v8Indication
Stage IVA Colorectal Cancer AJCC v8Indication
Stage IVB Colorectal Cancer AJCC v8Indication
Stage IVC Colorectal Cancer AJCC v8Indication
AdultIndication
Pancreatic AdenocarcinomaIndication
Recurrent Pancreatic CancerIndication
Gallbladder CancerIndication
Bile Duct CarcinomaIndication
Gallbladder CarcinomaIndication
Stage III Gallbladder Cancer AJCC v8Indication
Stage III Intrahepatic Bile Duct CancerIndication
Intrahepatic Bile Duct CancerIndication
Stage IV Distal Bile Duct Cancer AJCC v8Indication
Stage IV Gallbladder Cancer AJCC v8Indication
Gallbladder Cancer, Stage IVB, AJCC v8Indication
Metastatic Neuroendocrine CarcinomaIndication
Neuroendocrine CarcinomaIndication
Malignant NeoplasmIndication
Stage IV Cutaneous MelanomaIndication
fallopian tube carcinomaIndication
Metastatic Lung Non-Small Cell CarcinomaIndication
Metastatic MelanomaIndication
Cutaneous MelanomaIndication
Stage IIIC Cutaneous Melanoma AJCC v8Indication
Stage IIID Cutaneous Melanoma AJCC v8Indication
Primary Peritoneal CarcinomaIndication
Stage III Renal Cell Cancer AJCC v8Indication
Stage IIIA Lung CancerIndication
Stage IIIB Lung CancerIndication
Lung CancerIndication
Stage IV Renal Cell Cancer AJCC v8Indication
Lung Cancer Stage IVA AJCC v8Indication
Triple-Negative Breast CarcinomaIndication
melanomaIndication
Esophageal cancerIndication
Esophageal NeoplasmIndication
Head and Neck CancerIndication
Cancer of Unknown PrimaryIndication
Adult CholangiocarcinomaIndication
Stomach AdenocarcinomaIndication
Gastrointestinal NeoplasmIndication
Ampulla of Vater CancerIndication
Stage IIIB Gallbladder CancerIndication
Esophageal adenocarcinomaIndication
Esophageal AdenocarcinomaIndication
Pancreatic Adenosquamous CarcinomaIndication
Hodgkin lymphomaIndication
Metastatic Malignant NeoplasmIndication
Non-Hodgkin lymphomaIndication
Stage III Breast CancerIndication
Stage IIIA Breast CancerIndication
Ovarian Cancer AJCC Stage IIIA v6 and v7Indication
Breast CancerIndication
Breast cancerIndication
Adult RhabdomyosarcomaIndication
Childhood Embryonal RhabdomyosarcomaIndication
Childhood Soft Tissue SarcomaIndication
Adult Soft Tissue SarcomaIndication
Stage III Adult Soft Tissue SarcomaIndication
Metastatic Biliary Tract CarcinomaIndication
Digestive System NeoplasmIndication
Choroid Plexus CarcinomaIndication
NSCLCIndication
Gastric CancerClinical trial
A Phase 2, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Patients With Locally Advanced Unresectable or Metastatic Esophageal Squamous Cell Carcinoma That Progressed on or After Anti-PD-(L)1 Antibody TherapyStatus: Terminated, Estimated PCD: 2024-02-26
Clinical trial
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORSStatus: Active (not recruiting), Estimated PCD: 2024-06-24
Clinical trial
Phase 1 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or With Irinotecan, Irinotecan Plus Temozolomide, or With Cyclophosphamide Plus Topotecan in Pediatric Patients With Refractory Malignancies.Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Trial of RRx-001 in Combination With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 1b/2a Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Patients With Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-11-22
Clinical trial
An Open Label, Multi-cohort, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Envofolimab in Combination With BD0801 Injection With/Without Chemotherapy in Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-07-26
Clinical trial
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2024-03-15
Clinical trial
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell CarcinomaStatus: Completed, Estimated PCD: 2020-12-01
Clinical trial
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase II Study of AK112 With or Without AK117 for Patients With Metastatic Colorectal CancerStatus: Recruiting, Estimated PCD: 2024-12-25
Clinical trial
A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal CancerStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase Ill Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice as Second Line Treatment in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma After Failure of PD-1/PD-L1 Monoclonal Antibody in Combination With Platinum-based ChemotherapyStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal CancerStatus: Completed, Estimated PCD: 2019-02-11
Clinical trial
A Randomized, Multicenter, Phase Ⅱ/Ш Clinical Study to Evaluate the Efficacy of KN026 in Combination With Chemotherapy in Subjects With HER2 Positive Advanced Unresectable or Metastatic Gastric Cancer (Including Gastro-esophageal Junction Adenocarcinoma) Who Have Failed First-line Therapy.Status: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résectionStatus: Completed, Estimated PCD: 2022-05-27
Clinical trial
A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's SarcomaStatus: Recruiting, Estimated PCD: 2027-02-10
Clinical trial
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2.Status: Recruiting, Estimated PCD: 2025-05-02
Clinical trial
A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06BStatus: Recruiting, Estimated PCD: 2026-11-07
Clinical trial
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A.Status: Recruiting, Estimated PCD: 2024-11-08
Clinical trial
A Phase 1b/2 Trial to Evaluate the Efficacy and Safety of QLF31907 (PD-L1/4-1BB Bi-specific Antibody) Combination Therapy in Patients With Advanced Malignant TumorsStatus: Not yet recruiting, Estimated PCD: 2025-06-15
Clinical trial
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)Status: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric ResearchStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase 3 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66)Status: Recruiting, Estimated PCD: 2026-11-10
Clinical trial
Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 Combined With Irinotecan in the Treatment of Recurrent and Metastatic Esophageal Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCERStatus: Recruiting, Estimated PCD: 2025-01-06
Clinical trial
Phase I/II Study of KRN330 Plus Irinotecan After First-Line or Adjuvant FOLFOX/CapOx Failure in Patients With Metastatic Colorectal CancerStatus: Terminated, Estimated PCD: 2012-07-01
Clinical trial
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)Status: Completed, Estimated PCD: 2021-12-06
Clinical trial
A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's SarcomaStatus: Terminated, Estimated PCD: 2022-01-20
Clinical trial
Open, Randomized, Controlled, Multicenter Phase III Study Comparing CMAB009 Plus FOLFIRI Versus FOLFIRI Alone as First-line Treatment for Epidermal Growth Factor Receptor-expressing, RAS/BRAF Wild-type, Metastatic Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2022-05-06
Clinical trial
Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Unresectable or Metastatic Digestive System Malignancies (Colorectal and Gastric Cancer)Status: Terminated, Estimated PCD: 2022-06-06
Clinical trial
A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC).Status: Completed, Estimated PCD: 2020-04-28
Clinical trial
A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic CancerStatus: Completed, Estimated PCD: 2023-06-01
Clinical trial
A Randomized, Controlled, Open-label Phase Ⅱ Study of The Safety, Tolerability and Efficacy of JMT101 and Irinotecan Combined With SG001 in Patients With Metastatic Colorectal Cancer (mCRC)Status: Not yet recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase Ib/II , Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Effects of SC0245 in Combination With Irinotecan in Patients With ES-SCLCStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A 2-part Trial Comparing Overall Survival of Patients With Metastatic Ewing's Sarcoma Treated With Vigil Versus Gemcitabine and Docetaxel and to Determine Safety Profile of Vigil in Combination With Irinotecan and Temozolomide.Status: Completed, Estimated PCD: 2018-11-12
Clinical trial
A Phase 3 Trial of Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer After Platinum-Based Chemotherapy (BRAVA)Status: Withdrawn, Estimated PCD: 2021-10-22
Clinical trial
A Phase Ib/II Study of AK112 and AK119 in Combination With or Without Chemotherapy in the Treatment of Patients With Advanced Microsatellite Stabilized (pMMR/MSS) Colorectal CancerStatus: Not yet recruiting, Estimated PCD: 2024-05-10
Clinical trial
A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) Plus Binimetinib Alone or the Combination of Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Participants With Metastatic Colorectal Cancer (KEYNOTE-651)Status: Completed, Estimated PCD: 2021-09-08
Clinical trial
A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2023-06-14
Clinical trial
A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic AdenocarcinomaStatus: Completed, Estimated PCD: 2020-06-01
Clinical trial
A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Napabucasin ProtocolsStatus: Completed, Estimated PCD: 2021-05-15
Clinical trial
A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal CancerStatus: Completed, Estimated PCD: 2019-03-01
Clinical trial
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-03-07
Clinical trial
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic CancerStatus: Active (not recruiting), Estimated PCD: 2026-02-01
Clinical trial
PD-1 Antibody(Tislelizumab) Plus Irinotecan Combined With POF in Treatment Naive Advanced Gastric Cancer: A Phase II Study.Status: Not yet recruiting, Estimated PCD: 2024-04-11
Clinical trial
Multicenter Open-label, Phase II Trial, to Evaluate the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Patients With HER2-negative Breast Cancer (The Phenomenal Study)Status: Active (not recruiting), Estimated PCD: 2018-08-31
Clinical trial
A Pilot Phase II Trial Of Irinotecan Plus Carboplatin, And Irinotecan Maintenance Therapy (High-Risk Patients Only), Integrated Into The Upfront Therapy Of Newly Diagnosed Patients With Intermediate - And High-Risk RhabdomyosarcomaStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma, A Phase I StudyStatus: Completed, Estimated PCD: 2010-10-01
Clinical trial
A Phase I Study of a Combination of MM-398 and Veliparib in Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Phase I Trial of OSI-774 and CPT-11 in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2013-09-13
Clinical trial
A Randomised Study to Assess the Efficacy of Cetuximab Rechallenge in Patients With Metastatic Colorectal Cancer (RAS Wild-type) Responding to First-line Treatment With FOLFIRI Plus CetuximabStatus: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination With FOLFIRI in GI Malignancies With a Focus on Metastatic Colorectal and Gastric/Gastroesophageal CancersStatus: Active (not recruiting), Estimated PCD: 2024-03-29
Clinical trial
A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and IrinotecanStatus: Active (not recruiting), Estimated PCD: 2022-03-31
Clinical trial
A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid TumorsStatus: Completed, Estimated PCD: 2020-12-31
Clinical trial
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
ICE Study: a Clinical Study of the Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRCStatus: Recruiting, Estimated PCD: 2026-02-14
Clinical trial
A Phase I Study of Temozolomide, Oral Irinotecan, and Vincristine for Children With Refractory Solid TumorsStatus: Completed, Estimated PCD: 2009-06-01
Clinical trial
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 AmplificationStatus: Active (not recruiting), Estimated PCD: 2022-11-01
Clinical trial
NeoOPTIMIZE: An Open-Label, Phase II Trial to Assess the Efficacy of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients With Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-04-15
Clinical trial
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic CancerStatus: Active (not recruiting), Estimated PCD: 2019-05-01
Clinical trial
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade GliomasStatus: Active (not recruiting), Estimated PCD: 2022-02-21
Clinical trial
A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Clinical trial
A Pilot Protocol Evaluating Safety of Using the Medtronic Pump and Codman Catheter for the Delivery of Hepatic Arterial Infusion (HAI) Chemotherapy in Patients With Colorectal Carcinoma or CholangiocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)Status: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-06-15
Clinical trial
A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Best Systemic ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Perioperative Versus Adjuvant FOLFIRINOX for Resectable Pancreatic Cancer: the PREOPANC-3 StudyStatus: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Phase I Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab, and Irinotecan in Patients With Advanced Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2026-12-31
Clinical trial
A Phase II Trial of Preoperative FOLFIRINOX Followed by Gemcitabine Based Chemoradiotherapy in Patients With Borderline Resectable Pancreatic AdenocarcinomaStatus: Terminated, Estimated PCD: 2021-11-01
Clinical trial
Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic CancerStatus: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance StatusStatus: Completed, Estimated PCD: 2017-02-28
Clinical trial
Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Biliary Tract CancersStatus: Completed, Estimated PCD: 2021-08-13
Clinical trial
A Pilot and Feasibility Study of PD-1 Blockade With Nivolumab in Combination With Chemotherapy in Patients With Borderline Resectable Pancreatic AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-04-15
Clinical trial
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)Status: Active (not recruiting), Estimated PCD: 2025-02-15
Clinical trial
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing ChemotherapyStatus: Completed, Estimated PCD: 2021-02-22
Clinical trial
Randomized Phase II Study of Preoperative Combined Modality Paclitaxel / Cisplatin / RT or Irinotecan / Cisplatin / RT Followed by Postoperative Chemotherapy With the Same Agents in Operable Adenocarcinoma of the EsophagusStatus: Completed, Estimated PCD: 2009-09-01
Clinical trial
A Phase I Study of AZD2281 in Combination With Irinotecan in Patients With Locally Advanced or Metastatic Incurable Colorectal CancerStatus: Completed, Estimated PCD: 2012-09-25
Clinical trial
A Phase II Study of Irinotecan and Taxotere With Concurrent Radiotherapy as a Preoperative Treatment in Resectable Esophageal CancerStatus: Completed
Clinical trial
Phase II Trial Of Weekly Irinotecan And Docetaxel In Recurrent Or Metastatic Head And Neck CarcinomaStatus: Completed, Estimated PCD: 2005-04-01
Clinical trial
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal MalignanciesStatus: Completed, Estimated PCD: 2017-12-01
Clinical trial
PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-06-08
Clinical trial
A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic CancerStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer: a Phase II, Single-arm StudyStatus: Not yet recruiting, Estimated PCD: 2024-04-05
Clinical trial
A Randomized Investigation of Side Effects to FOLFOXIRI in Combination With Tocotrienol or Placebo as First Line Treatment of Metastatic Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2019-08-01
Clinical trial
Phase II Trial of Irinotecan/Docetaxel for Advanced Pancreatic Cancer, With Randomization Between Irinotecan/Docetaxel and Irinotecan/Docetaxel Plus C225 a Monoclonal Antibody to the Epidermal Growth Factor Receptor (EGF-r)Status: Completed, Estimated PCD: 2009-06-01
Clinical trial
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS)Status: Completed, Estimated PCD: 2014-12-31
Clinical trial
Phase Ib/II Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs) in Combination With Low Dose IL-2 and GM-CSFStatus: Completed, Estimated PCD: 2021-06-21
Clinical trial
Phase I Study of Irinotecan Liposome (Nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of Both Unselected and Selected (for BRCA 1/2 and PALB2 Mutations) Patients With Metastatic Adenocarcinoma of the Pancreas Then Followed by a Phase II Study of First Line Treatment of Selected Patients With Metastatic Adenocarcinoma of the Pancreas With Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)Status: Active (not recruiting), Estimated PCD: 2021-03-31
Clinical trial
A Phase II Trial of Adebrelimab in Combination With NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-06-01